Följ
Emanuel Krebs
Emanuel Krebs
Senior Health Economist, BC Cancer
Verifierad e-postadress på bccrc.ca
Titel
Citeras av
Citeras av
År
Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users
L Wang, JE Min, E Krebs, E Evans, D Huang, L Liu, YI Hser, B Nosyk
International Journal of Drug Policy 49, 32-40, 2017
1172017
The costs of crime during and after publicly funded treatment for opioid use disorders: a population‐level study for the state of California
E Krebs, D Urada, E Evans, D Huang, YI Hser, B Nosyk
Addiction 112 (5), 838-851, 2017
552017
Ending the HIV epidemic in the USA: an economic modelling study in six cities
B Nosyk, X Zang, E Krebs, B Enns, JE Min, CN Behrends, C Del Rio, ...
The Lancet HIV 7 (7), e491-e503, 2020
542020
Cost-effectiveness of publicly funded treatment of opioid use disorder in California
E Krebs, B Enns, E Evans, D Urada, MD Anglin, RA Rawson, YI Hser, ...
Annals of internal medicine 168 (1), 10-19, 2018
502018
The Impact of Localized Implementation: Determining the Cost-Effectiveness of HIV Prevention and Care Interventions Across Six United States Cities
E Krebs, X Zang, B Enns, JE Min, C Behrends, C Del Rio, JC Dombrowski, ...
AIDS 34 (3), 447-458, 2020
452020
Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996–2013: a modelling study
B Nosyk, X Zang, JE Min, E Krebs, VD Lima, MJ Milloy, J Shoveller, ...
The lancet HIV 4 (7), e303-e310, 2017
442017
The potential epidemiological impact of coronavirus disease 2019 (COVID-19) on the human immunodeficiency virus (HIV) epidemic and the cost-effectiveness of linked, opt-out HIV …
X Zang, E Krebs, S Chen, M Piske, WS Armstrong, CN Behrends, ...
Clinical Infectious Diseases 72 (11), e828-e834, 2021
42*2021
The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study
A Borquez, L Beletsky, B Nosyk, SA Strathdee, A Madrazo, D Abramovitz, ...
The Lancet Public Health 3 (9), e429-e437, 2018
422018
Developing a dynamic HIV transmission model for 6 US cities: an evidence synthesis
E Krebs, B Enns, L Wang, X Zang, D Panagiotoglou, C Del Rio, ...
PloS one 14 (5), e0217559, 2019
402019
“Ending the epidemic” will not happen without addressing racial/ethnic disparities in the United States human immunodeficiency virus epidemic
B Nosyk, E Krebs, X Zang, M Piske, B Enns, JE Min, CN Behrends, ...
Clinical Infectious Diseases 71 (11), 2968-2971, 2020
342020
Development and calibration of a dynamic HIV transmission model for 6 US cities
X Zang, E Krebs, JE Min, A Pandya, BDL Marshall, BR Schackman, ...
Medical Decision Making 40 (1), 3-16, 2020
312020
Cost-effectiveness analysis along the continuum of HIV care: how can we optimize the effect of HIV treatment as prevention programs?
B Nosyk, E Krebs, O Eyawo, JE Min, R Barrios, JSG Montaner
Current HIV/AIDS Reports 11, 468-478, 2014
292014
Dynamics in the costs of criminality among opioid dependent individuals
E Krebs, T Kerr, J Montaner, E Wood, B Nosyk
Drug and alcohol dependence 144, 193-200, 2014
282014
Increased drug use and the timing of social assistance receipt among people who use illicit drugs
E Krebs, L Wang, M Olding, K DeBeck, K Hayashi, MJ Milloy, E Wood, ...
Social Science & Medicine 171, 94-102, 2016
262016
Ending the epidemic in America will not happen if the status quo continues: modeled projections for human immunodeficiency virus incidence in 6 US cities
B Nosyk, X Zang, E Krebs, JE Min, CN Behrends, C Del Rio, ...
Clinical Infectious Diseases 69 (12), 2195-2198, 2019
252019
Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study
L Wang, E Krebs, JE Min, WC Mathews, A Nijhawan, C Somboonwit, ...
The Lancet HIV 6 (8), e531-e539, 2019
242019
Characterizing long-term health related quality of life trajectories of individuals with opioid use disorder
E Krebs, T Kerr, E Wood, B Nosyk
Journal of substance abuse treatment 67, 30-37, 2016
232016
Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia …
M Piske, T Thomson, E Krebs, N Hongdilokkul, J Bruneau, S Greenland, ...
BMJ open 10 (9), e036102, 2020
212020
The costs of crime associated with stimulant use in a Canadian setting
B Enns, E Krebs, K DeBeck, K Hayashi, MJ Milloy, L Richardson, E Wood, ...
Drug and alcohol dependence 180, 304-310, 2017
212017
Cost-effectiveness analysis in implementation science: a research agenda and call for wider application
E Krebs, B Nosyk
Current HIV/AIDS Reports 18, 176-185, 2021
202021
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20